- Home
- PFO vs MDXH Comparison
PFO vs MDXH Comparison
Compare PFO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- MDXH
- Stock Information
- Founded
- PFO 1991
- MDXH 2003
- Country
- PFO United States
- MDXH Belgium
- Employees
- PFO N/A
- MDXH N/A
- Industry
- PFO Finance Companies
- MDXH
- Sector
- PFO Finance
- MDXH
- Exchange
- PFO Nasdaq
- MDXH Nasdaq
- Market Cap
- PFO 121.4M
- MDXH 141.1M
- IPO Year
- PFO N/A
- MDXH 2021
- Fundamental
- Price
- PFO $9.76
- MDXH $4.73
- Analyst Decision
- PFO
- MDXH Buy
- Analyst Count
- PFO 0
- MDXH 1
- Target Price
- PFO N/A
- MDXH $6.00
- AVG Volume (30 Days)
- PFO 31.8K
- MDXH 188.0K
- Earning Date
- PFO 01-01-0001
- MDXH 11-05-2025
- Dividend Yield
- PFO 6.51%
- MDXH N/A
- EPS Growth
- PFO N/A
- MDXH N/A
- EPS
- PFO N/A
- MDXH N/A
- Revenue
- PFO N/A
- MDXH $98,953,000.00
- Revenue This Year
- PFO N/A
- MDXH $24.40
- Revenue Next Year
- PFO N/A
- MDXH $22.29
- P/E Ratio
- PFO N/A
- MDXH N/A
- Revenue Growth
- PFO N/A
- MDXH 22.56
- 52 Week Low
- PFO $6.90
- MDXH $1.35
- 52 Week High
- PFO $8.51
- MDXH $4.94
- Technical
- Relative Strength Index (RSI)
- PFO 65.34
- MDXH 71.74
- Support Level
- PFO $9.73
- MDXH $4.51
- Resistance Level
- PFO $9.90
- MDXH $4.94
- Average True Range (ATR)
- PFO 0.08
- MDXH 0.29
- MACD
- PFO -0.01
- MDXH -0.00
- Stochastic Oscillator
- PFO 44.77
- MDXH 82.45
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.